Evaxion Biotech A/S
EVAX3.360USD
+0.450+15.46%
Close 02/06, 16:00（ET）Quotes delayed by 15 min
1.06BMarket Cap
LossP/E TTM
More Details of Evaxion Biotech A/S Company
Evaxion A/S, formerly known as Evaxion Biotech A/S, is a Denmark-based clinical-stage biotechnology company, which specializes in the development of AI-driven immunotherapies to improve the lives of patients with cancer and infectious diseases. The Company decodes the human immune system to discover and develop immunotherapies to treat cancer and infectious diseases. Based on AI-immunology core technology, Evaxion is developing a pipeline of product candidates. In addition, Evaxion develops portfolio of vaccines to prevent bacterial and viral infections.
Evaxion Biotech A/S Info
Ticker SymbolEVAX
Company nameEvaxion A/S
IPO dateFeb 05, 2021
CEO- -
Number of employees46
Security typeDepository Receipt
Fiscal year-endFeb 05
AddressDr. Neergaards Vej 5F
CityHOERSHOLM
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryDenmark
Postal code2970
Phone
Websitehttps://evaxion.ai/
Ticker SymbolEVAX
IPO dateFeb 05, 2021
CEO- -
Company Executives of Evaxion Biotech A/S
Name
Name/Position
Position
Shareholding
Change
,
,
--
--
Name
Name/Position
Position
Shareholding
Change
,
,
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Sat, Feb 7
Updated: Sat, Feb 7
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Merck & Co Inc
15.32%
Merck Sharp & Dohme Corporation
3.06%
Ikarian Capital LLC
1.01%
PSM Vermögensverwaltung GmbH
0.44%
Boothbay Fund Management, LLC
0.30%
Other
79.86%
Shareholders
Shareholders
Proportion
Merck & Co Inc
15.32%
Merck Sharp & Dohme Corporation
3.06%
Ikarian Capital LLC
1.01%
PSM Vermögensverwaltung GmbH
0.44%
Boothbay Fund Management, LLC
0.30%
Other
79.86%
Shareholder Types
Shareholders
Proportion
Corporation
18.39%
Hedge Fund
1.01%
Investment Advisor
0.64%
Investment Advisor/Hedge Fund
0.36%
Bank and Trust
0.13%
Other
79.49%
Institutional Shareholding
Updated: Mon, Dec 8
Updated: Mon, Dec 8
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
24
119.22K
2.61%
--
2025Q3
29
119.22K
2.84%
-1.16K
2025Q2
30
120.38K
3.25%
-17.31K
2025Q1
30
137.73K
1.10%
+68.46K
2024Q4
27
56.73K
8.80%
-56.79K
2024Q3
27
111.11K
9.19%
+19.03K
2024Q2
28
91.47K
7.84%
+14.46K
2024Q1
28
77.00K
2.12%
+54.93K
2023Q4
28
9.74K
18.41%
+6.27K
2023Q3
29
3.47K
3.61%
-551.00
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Merck & Co Inc
1.21M
15.32%
--
--
Sep 30, 2025
Merck Sharp & Dohme Corporation
242.82K
3.06%
+134.37K
+123.89%
Jan 31, 2025
Ikarian Capital LLC
80.00K
1.01%
--
--
Sep 30, 2025
Boothbay Fund Management, LLC
23.73K
0.3%
--
--
Sep 30, 2025
Rhumbline Advisers Ltd. Partnership
9.44K
0.12%
--
--
Sep 30, 2025
GAMMA Investing LLC
3.84K
0.05%
+533.00
+16.11%
Dec 31, 2025
UBS Financial Services, Inc.
1.00
0%
-2.04K
-99.95%
Sep 30, 2025
View more
Related ETFs
Name
Proportion
No Data
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Splits
Date
Ex-dividend Date
Type
Ratio
Dec 27, 2024
Merger
5→1
Dec 27, 2024
Merger
5→1
Dec 27, 2024
Merger
5→1
Dec 27, 2024
Merger
5→1
Jan 08, 2024
Merger
10→1
Jan 08, 2024
Merger
10→1
Date
Ex-dividend Date
Type
Ratio
Dec 27, 2024
Merger
5→1
Dec 27, 2024
Merger
5→1
Dec 27, 2024
Merger
5→1
Dec 27, 2024
Merger
5→1
Jan 08, 2024
Merger
10→1
Jan 08, 2024
Merger
10→1
Jan 08, 2024
Merger
10→1
Jan 08, 2024
Merger
10→1
